Aurobindo Pharma secures USFDA approval for Droxidopa Capsules
Hyderabad: Drugmaker, Aurobindo Pharma Limited, has recently announced that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Droxidopa Capsules, 100 mg, 200 mg and 300 mg.
Droxidopa Capsules are generic version of Lundbeck NA Ltd's Northera Capsules. The product will be launched immediately.
The approved product has an estimated market size of US$ 352 million for the twelve months ending December 2020, according to IQVIA.
Droxidopa is indicated for the treatment of orthostatic dizziness and lightheadedness in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure, dopamine beta-hydroxylase deficiency and non-diabetic autonomic neuropathy.
This is the 24th ANDA to be approved out of Unit-X formulation facility in Hyderabad, India used for manufacturing oral products.
Aurobindo now has a total of 469 ANDA approvals (440 Final approvals and 29 tentative approvals) from USFDA.
Read also: Aurobindo Pharma net profit jumps over 4-fold to Rs 2,946.32 crore in Q3
Aurobindo Pharma Limited, headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients.
The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd